[3-(1H-咪唑-1-基)丁基]胺 | 93668-14-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: [3-(1H-咪唑-1-基)丁基]胺
• 中文别名: 3-咪唑基-1-基正丁胺
• 英文名称: 3-(1H-imidazol-1-yl)butanamine
• 英文别名: 3-(1H-imidazol-1-yl)butan-1-amine；gamma-methyl-1H-imidazole-1-propanamine；3-imidazol-1-ylbutan-1-amine
• CAS: 93668-14-5
• 化学式: C₇H₁₃N₃
• 分子量: 139.2
• InChiKey: WAZALYDSTDIFIY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933290090

反应信息

• 作为反应物：
  描述：

  [3-(1H-咪唑-1-基)丁基]胺 在 氢氧化钾 、 乙醇 作用下， 以 四氢呋喃 为溶剂， 反应 5.0h， 生成 3-[3-(1H-imidazol-1-yl)butyl]-6-methyl-2,4(1H,3H)-quinazolinedione
  参考文献：
  名称：

  Thromboxane synthetase inhibitors and antihypertensive agents. 4. N-[(1H-imidazol-1-yl)alkyl] derivatives of quinazoline-2,4(1H,3H)-diones, quinazolin-4(3H)-ones, and 1,2,3-benzotriazin-4(3H)-ones

  摘要：

  The quinazolinedione, quinazolinone, and 1,2,3-benzotriazinone title compounds were prepared as analogues of N-[(1H-imidazol-1-yl)alkyl]-1H-isoindole-1,3(2H)-diones which were the subject of a previous report from our laboratories. These compounds were evaluated as thromboxane (TX) synthetase inhibitors and as antihypertensive agents. While each series of compounds had activity both as TX synthetase inhibitors and as antihypertensives, the best compounds were N-[(1H-imidazol-1-yl)alkyl]quinazoline-2,4(1H,3H]-diones (V). In general these compounds were all selective enzyme inhibitors at least equipotent with the standard dazoxiben. These compounds were also very active antihypertensive agents as determined in SHR. The SAR is discussed for both types of activity. Compound 20a was further evaluated for TX formation inhibiting properties in several other platelet types both in vitro and ex vivo and is between 100 and 1000 times more potent than dazoxiben.

  DOI：

  10.1021/jm00395a016
• 作为产物：
  描述：

  3-imidazol-1-yl-butyronitrile 在 镍 ammonium hydroxide 、 氢气 作用下， 以 甲醇 为溶剂， 生成 [3-(1H-咪唑-1-基)丁基]胺
  参考文献：
  名称：

  血栓烷合成酶抑制剂和降压药。1. N-[（（1H-咪唑-1-基）烷基]芳基酰胺和N-[（1H-1,2,4-三唑-1-基）烷基]芳基酰胺。

  摘要：

  制备标题化合物以研究其作为血栓烷合成酶抑制剂以及降压药的潜力。制备咪唑VIII和三唑X以检查芳族取代，链长和杂环取代对生物活性的影响。咪唑VIII和三唑X是不抑制前列环素形成的血栓烷合成酶抑制剂。制备的最有趣的血栓烷合成酶抑制剂是（1H-咪唑-1-基）烷基胺的4-氯-，4-（三氟甲基）-和4-溴苯甲酰胺衍生物，其C5-C8烷基链将杂环与酰胺部分分开，而最具活性的降压药是带有C3烷基链的3-或4-氯-，-溴或-（三氟甲基）苯甲酰胺。

  DOI：

  10.1021/jm00154a017

文献信息

• N-[2-4-(1H-Imidazol-1-yl)alkyl]-arylamides and pharmaceutical
  申请人：American Cyanamid Company

  公开号：US04568687A1

  公开（公告）日：1986-02-04

  This disclosure describes novel N-[.omega.-(1H-imidazol-1-yl)alkyl]arylamides which possess the property of inhibiting the enzyme thromboxane synthetase and are also useful in the treatment of hypertension and myocardial ischemia.

  这份披露描述了一种新颖的N-[.omega.-(1H-咪唑-1-基)烷基]芳基酰胺，具有抑制血栓素合酶酶活性的特性，并且在治疗高血压和心肌缺血方面也很有用。
• Imidazole‐Based Synthetic Lipidoids for In Vivo mRNA Delivery into Primary T Lymphocytes
  作者：Xuewei Zhao、Jinjin Chen、Min Qiu、Yamin Li、Zachary Glass、Qiaobing Xu

  DOI：10.1002/anie.202008082

  日期：2020.11.2

  Engineering T lymphocytes is an emerging approach in a variety of biomedical applications. However, delivering large biologics to primary T lymphocytes directly in vivo is technically challenging due to the low transfection efficacy. Herein, we investigated a library of synthetic lipid‐like molecules (lipidoids) for their capability of delivering mRNA into primary T lymphocytes both ex vivo and in vivo. We

  工程T淋巴细胞是各种生物医学应用中的新兴方法。然而，由于转染效率低，直接在体内将大量生物制剂直接递送至原代T淋巴细胞在技术上具有挑战性。本文中，我们研究了合成脂质样分子（类脂质）库在体外和体内将mRNA传递至原代T淋巴细胞的能力。最初，我们筛选了一个具有大量结构脂质的离体文库，并鉴定了在T淋巴细胞转染中特别有效的含咪唑的脂质。我们通过构建和筛选包含咪唑或咪唑类似物的详细类脂质库来进行结构-活性相关分析，从而进一步优化类脂质结构。
• 3-heteroalkyl-2,4.quinzaoline-diones
  申请人：AMERICAN CYANAMID COMPANY

  公开号：EP0293500A1

  公开（公告）日：1988-12-07

  A compound is described which is selected from the group consisting of those of the formula: wherein A is a divalent moiety of the formula: or and n is an integer from 2-10, inclusive; R is hydrogen, oxygen or alkyl having from one to four carbon atoms; Z is C or N; and when Z is N, --- is ――― and there is no R substituent, when Z is C and R is oxygen, --- is ―――; and when Z is C and R is alkyl, --- is ――― ; R6 is hydrogen or alkyl having from one to four carbon atoms; R1 and R2 may be the same or different and may be selected from the group consisting of hydrogen, halogen, trifluoromethyl, alkoxy having from one to four carbon atoms, alkyl having from one to four carbon atoms, nitro and amino; wherein Heteroaryl is wherein R3 and R4 may be selected from hydrogen, alkyl having from one to four carbon atoms, or phenyl; and X is CH or N, together with the pharmaceutically acceptable salts thereof as well as a process for producing the same and its use for pharmaceutical processes.

  描述了一种化合物，所选自以下组合中的一种，其化学式为：其中A是化学式的二价基团：或者n为2-10之间的整数；R为氢、氧或具有1-4个碳原子的烷基；Z为C或N；当Z为N时，---为―――且没有R取代基，当Z为C且R为氧时，---为―――；当Z为C且R为烷基时，---为―――；R6为氢或具有1-4个碳原子的烷基；R1和R2可以相同也可以不同，可选自氢、卤素、三氟甲基、具有1-4个碳原子的烷氧基、具有1-4个碳原子的烷基、硝基和氨基；其中Heteroaryl为其中R3和R4可以选择自氢、具有1-4个碳原子的烷基或苯基；X为CH或N，以及其药学上可接受的盐，以及用于生产该化合物的过程及其在制药过程中的应用。
• 3-heteroarylalkyl-4-quinazolinones
  申请人：American Cyanamid Company

  公开号：US04710502A1

  公开（公告）日：1987-12-01

  Novel 3-heteroarylalkyl-4-quinazolinones which are useful as inhibitors of thromboxane synthetase and/or as antihypertensive agents in the treatment of hypertension and myocardial ischemia.

  新型3-杂环芳基烷基-4-喹唑啉酮，可用作血栓素合酶抑制剂和/或抗高血压药物，用于治疗高血压和心肌缺血。
• N-[(1H-imidazol-1-yl)alkyl]benz[cd]-indol-2-amines and use in inhibiting
  申请人：American Cyanamid Company

  公开号：US04728663A1

  公开（公告）日：1988-03-01

  N-[(1H-imidazol-1-yl)alkyl]benz[cd]-indol-2 amines useful as inhibitors of thromboxane synthetase enzyme, hypotensive agents and cardioprotective agents are described.

  描述了作为血栓素合酶酶抑制剂、降压剂和心脏保护剂的N-[(1H-咪唑-1-基)烷基]苯[cd]-吲哚-2胺。